Diabetes Complications
📧 Sign up to get email alerts when something new happens for Diabetes Complications.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-08-03EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
EMA authorises Vabysmo (faricimab) for wet macular degeneration, macular edema, and diabetes-related eye complications.
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
-
EMA approval · 2026-06-15EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular de…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2024-03-26EMA Authorised: Ximluci (ranibizumab) — STADA Arzneimittel AG
European Medicines Agency authorised Ximluci (ranibizumab) for indications including wet age-related macular degeneration, macular edema, an…